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Abstract  58 
 59 
Development of SARS-CoV-2 vaccines and therapeutics will depend on understanding viral 60 
immunity. We studied T-cell memory in 42 patients following recovery from COVID-19 (28 61 
mild, 14 severe, 16 unexposed donors), using IFN-γ-based assays with peptides spanning 62 
SARS-CoV-2 except ORF1. The breadth and magnitude of T-cell responses were 63 
significantly higher in severe compared to mild cases. Total and spike-specific T-cell 64 
responses correlated with spike-specific antibody responses.  We identified 41 peptides 65 
containing CD4+ and/or CD8+ epitopes, including six immunodominant regions.  Six 66 
optimised CD8+ epitopes were defined, with peptide-MHC-pentamer-positive cells displaying 67 
central- and effector-memory phenotype. In mild cases, higher proportions of SARS-CoV-2-68 
specific CD8+ T-cells were observed. The identification of T-cell responses associated with 69 
milder disease, will support an understanding of protective immunity, and highlights the 70 
potential of including non-spike proteins within future COVID-19 vaccine design. 71 
  72 
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Introduction  73 
 74 
COVID-19 is caused by the recently emerged Severe Acute Respiratory Syndrome 75 
coronavirus-2 (SARS-CoV-2). Whilst the majority of COVID-19 infections are relatively mild, 76 
with recovery typically within two to three weeks1, 2, a significant number of patients develop 77 
severe illness, which is postulated to be related to both an overactive immune response and 78 
viral-induced pathology3, 4. The role of T-cell immune responses in disease pathogenesis 79 
and longer-term protective immunity is currently poorly defined, but essential to understand 80 
in order to  inform  therapeutic interventions and vaccine design.  81 
 82 
Currently, there are many ongoing vaccine trials, but it is unknown whether they will provide 83 
long lasting protective immunity.  Most vaccines are designed to induce  antibodies to the 84 
SARS-CoV-2 spike protein, but it is not yet known if this will be sufficient to induce full 85 
protective immunity to SARS-CoV-25,6, 7,8. Studying natural immunity to the virus, including 86 
the role of SARS-CoV-2-specific T-cells is critical to fill the current knowledge gaps for 87 
improved vaccine design. 88 
 89 
For many primary virus infections, it typically takes 7-10 days to prime and expand adaptive 90 
T-cell immune responses in order to control the virus9. This coincides with the typical time it 91 
takes for COVID-19 patients to either recover or develop severe illness. There is an 92 
incubation time of 4-7 days before symptom onset, and a further 7-10 days before 93 
individuals progress to severe disease10. Such a pattern of progression raises the possibility 94 
that a poor T cell response contributes to SARS-CoV-2 viral persistence and COVID-19 95 
mortality, whereas strong T cell responses are protective in the majority of individuals. 96 
 97 
Evidence supporting a role for T cells in COVID-19 protection and pathogenesis is currently 98 
incomplete and sometimes conflicting3,11,12,13,14. To date there have been few studies 99 
analysing SARS-CoV-2-specific T-cell responses and their role in disease progression 15, 100 
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although virus specific T cells have been shown to be protective in human influenza 101 
infection16. In a study of CD4+ and CD8+ T-cell responses to SARS-CoV-2 in non-102 
hospitalised convalescent subjects, Grifoni et al  found that all recovered subjects 103 
established CD4+ responses and 70% established CD8+ memory responses to SARS-CoV-104 
217. SARS-CoV-2-specific CD4+ T-cell responses were also frequently observed in 105 
unexposed subjects in their study, suggesting the possibility of pre-existing cross-reactive 106 
immune memory to seasonal coronaviruses. In Singapore, Le Bert et al18  found long lasting 107 
T cell immunity  to the original SARS coronavirus nucleoprotein  (NP) in those that were 108 
infected in 2003. These T cells cross-reacted with SARS-CoV-2 NP, and T cells cross 109 
reactive  with NSP7 and NSP13 of other coronaviruses were also present in those 110 
uninfected with either SARS coronaviruses18. 111 
 112 
In the present study, the overall and immunodominant SARS-CoV-2–specific memory T-cell 113 
response in subjects who had recovered from COVID-19 were evaluated ex vivo using 114 
peptides spanning the full proteome of the SARS-CoV-2, except for ORF-1. Epitopes were 115 
identified using two-dimensional matrix peptide pools and CD4+ and CD8+ T cell responses 116 
were distinguished. The epitope specificity and HLA restriction of the dominant CD8+ T-cell 117 
responses were defined in ex vivo  assays and using in vitro cultured short-term T-cell lines.  118 
The ex vivo functions of SARS-CoV-2-specific T-cells specific for dominant epitopes were 119 
evaluated by their intracellular cytokine production profiles. Broad, and frequently strong, 120 
SARS-CoV-2 specific CD4+ and CD8+ T-cell responses were seen in the majority of 121 
convalescent patients, with significantly larger overall T-cell responses in those that had 122 
severe compared to mild disease.  However, there was a greater proportion of CD8+ T-cell 123 
compared to CD4+ T cell responses in mild cases with higher frequencies of multi-cytokine 124 




Study subjects 128 
42 individuals were recruited following recovery from COVID-19, including 28 mild cases and 129 
14 severe cases. In addition, 16 control individuals sampled in 2017-2019, before COVID-19 130 
appeared, were studied in parallel.  Supplementary Fig. 1 shows the participant 131 
characteristics.  No significant differences in gender or age were noted between mild and 132 
severe groups. The SaO2/FiO2 ratio in severe cases ranged from 4.3 (where 4.5 would be 133 
the estimate for an individual with mild disease breathing ambient air) to 1.6 with the patients 134 
with critical disease having an estimate of 0.8 (median in severe group 3.8). 135 
 136 
Ex vivo assessment of memory T cell responses specific to SARS-CoV-2  137 
PBMCs were tested for responses to a panel of 423 overlapping peptides spanning the 138 
SARS-CoV-2 proteome except ORF1, using ex vivo IFN-γ ELISpot assays. All overlapping 139 
peptides were placed into two 2-dimensional peptide matrices: a total of 61 peptide pools 140 
were tested, with 29 peptides in the first-dimension pools, as described in Supplementary 141 
Table 1. The majority of the participants exhibited SARS-CoV-2 memory T cell responses to 142 
at least one of the peptides. The overall distribution,  magnitude  and breadth of the IFN-γ 143 
responses against all SARS-CoV-2 virus peptides are shown in Fig. 1. There was no 144 
correlation between the T cell responses and the time that had elapsed from symptom 145 
development (Supplementary Fig. 2).  No ex vivo IFN-γ-producing SARS-CoV-2-specific T 146 
cell responses were observed in healthy volunteers, who were all sampled before any 147 
chance of exposure, but in those with appropriate HLA types, T cell responses were 148 
observed to influenza virus, EBV, CMV (FEC) using pools of known T cell epitopes as well 149 
as PHA as positive controls  (Supplementary Fig. 3). The breadth and magnitude of the T 150 
cell responses varied considerably between individuals. T cell responses were detected 151 
against epitopes distributed across a wide variety of virus proteins. Significantly higher 152 
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magnitude (p=0.002) and broader (p=0.002) overall T cell responses were observed in 153 
severe cases in comparison with mild cases, in particular for responses to spike 154 
(magnitude/breadth, p=0.021/0.016), membrane (magnitude/breadth, 155 
p<p+0.0003/p=0.033),ORF3(magnitude/breadth, p<0.0001/0.001) and ORF8 156 
(magnitude/breadth, p=0.011/0.014)  proteins (Fig. 2). Overall, we found strong and broad T 157 
cell memory responses were induced after recovery from COVID-19, and the breadth and 158 
magnitude of T-cell responses were significantly higher in severe compared to mild cases. 159 
 160 
Correlation with spike specific antibody responses 161 
The relationship between spike-specific, and overall T cell responses in association with 162 
spike-specific, receptor binding domain (RBD) and NP-specific antibody endpoint titres 163 
(EPTs) was assessed (Fig. 3). There were significant correlations between (a) spike-specific 164 
antibody titers and both overall T cell responses (p=0.0004/R=0.5185) and spike-specific T 165 
cell responses (p=0.0006/R=0.505); (b) RBD-specific antibody titers and both overall T cell 166 
responses (p=0.0004/R=0.5198) and spike-specific T cell responses (p=0.0004/R=0.5189);  167 
and (c) NP-specific antibody titers and both overall T cell responses (p=0.0015/R=0.4738) 168 
and spike-specific T cell responses (p=0.007/R=0.412). However, there was no significant 169 
association between NP-specific antibody titers and NP-specific T cell responses 170 
(p=0.067/R= 0.286); (Fig. 3a-c; and Supplementary Fig. 4). Moreover, significantly higher 171 
level of spike, RBD and NP EPTs were observed in severe cases in comparison with mild 172 
cases (Fig. 3d). It was noted that some individuals had low RBD-specific antibodies (Fig. 173 
3b), yet had detectable spike-specific antibodies (Fig. 3a), suggesting that antibodies were 174 
able to target non-RBD regions of spike – these are under further investigation. Thus total 175 
and spike-specific T-cell responses  were found to be correlated with spike-specific antibody 176 
responses. 177 
 178 
Distribution of SARS-CoV-2–specific CD4+ and CD8+ memory T cell responses  179 
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Having identified overall T cell responses to SARS-CoV-2 peptides, the responses detected 180 
against positive peptide pools were characterized by flow cytometry for peptide recognition 181 
by CD4+ or CD8+ T cell subsets and for intracellular production of IFN-γ, TNF- and IL-2 182 
after stimulation (Fig. 4a-b and Supplementary Fig. 5).  A greater proportion of the T cell 183 
responses to spike (p=0.0268) and M/NP (p=0.02) were contributed to by CD8+ T cells in 184 
those with mild disease compared to those with severe disease (Fig. 4c, Supplementary Fig. 185 
6a). Differential subsets of SARS-CoV-2-specific T cells therefore associate with clinical 186 
outcome.  187 
 188 
Evaluation of the polyfunctionality of T cells responding to SARS-CoV-2 peptides 189 
Multi-cytokine analysis revealed patterns of IFN-γ, TNF and IL-2 production by CD4+ and 190 
CD8+ T cells in both mild and severe cases (Fig. 5a), For 22 individuals tested, both CD4+ 191 
and CD8+ antigen-specific-T cells produced least one of these three cytokines and others in 192 
combination. CD8+ but not CD4+ T cells targeting different virus proteins showed different 193 
cytokine profiles, with the M/NP-specific CD8+ T cells showing wider functionality than T cells 194 
targeting spike protein (p=0.0231, Fig. 5b and Supplementary Fig. 6b). Furthermore, there 195 
were a greater proportion of multifunctional M/NP-specific CD8+ T cells compared to spike-196 
specific T cells in those that had mild disease (p=0.0037), but not in those that had severe 197 
disease (p=0.3823). In contrast to observations seen in influenza virus infection19 , we did 198 
not observe significant differences in the cytotoxic potential (as indicated by expression of 199 
the degranulation marker CD107a) in patients with mild and severe disease (Fig. 5c); and 200 
we observed very few CD107a+ CD4+ T cells overall, suggesting cytotoxic CD4+ T cells 201 
might not be a major contributor to virus clearance.  202 
 203 
Identification of SARS-CoV-2 specific T cell peptides containing epitopes  204 
IFN-γ ELISpot assays were performed with candidate peptides identified from the 2-205 
dimensional matrix analysis in 34 subjects. A total of 41 peptides containing SARS-CoV-2 T 206 
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cell epitope regions were recognized by COVID-19 convalescent subjects, 18 from spike, 10 207 
from NP, 6 from membrane and 7 from ORF proteins.  Strikingly, 6 dominant 18mer peptides 208 
were recognised by 6 or more of 34 subjects tested (Table 1). NP-16 was recognised by 209 
12/34 (35%) subjects tested and contained at least two epitopes which recognised by either 210 
CD4+ T cells or CD8+ T cells. 211 
 212 
M-24 was recognised by 16/34 subjects (47%) tested and contained one or more CD4+ T 213 
cell epitopes. Peptide M-20 was recognised by 11/34 subjects tested (32%) and contained 214 
one or more CD4+ T cell epitopes. 3 dominant spike peptides were also identified, with S-34 215 
recognised by 10/34 subjects (29%) containing both CD4+ and CD8+ T cell epitopes, and a 216 
further two spike peptides S-151 and S-174 were recognised by 8/34 and 6/34 subjects (24% 217 
and 18%), both containing CD4+ T cell epitopes.  218 
 219 
Those dominant responses were further confirmed by ex-vivo assays and by using cultured 220 
short-term T cell lines. Supplementary Fig. 7 illustrates examples of FACS plots from 221 
intracellular cytokine staining (ICS) when short-term T cell lines were stimulated with single 222 
peptides containing epitopes. CD4+ T cells elicited strong responses against dominant spike 223 
peptides and M peptides, whereas cells targeting two NP dominant peptides were CD8+ T 224 
cells. The optimal epitopes within the long peptides recognized by dominant CD8+ T cells 225 
and their HLA restriction, matched to the donor’s HLA type,  were predicted using the  IEDB 226 
analysis resource  (http://tools.iedb.org/mhci). The best predicted epitope sequences are 227 
shown in supplementary Table 2.   228 
 229 
A set of previously defined SARS epitopes20 with identical sequences to SARS-CoV-2 were 230 
also tested by ELISpot assay  (Supplementary Table 3),  Most of those peptides did not elicit 231 
any positive responses in 42 COVID-19 recovered subjects, apart from two NP epitope 232 
peptides (N-E-3 MEVTPSGTWL and N-E-11 LLNKHIDAYKTFPPTEPK) and one spike 233 
epitope peptide (S-E-19 QLIRAAEIRASANLAATK) . N-E-11, which is identical to peptide 234 
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NP-51, shares the sequence with two other known HLA-A*0201 restricted SARS epitopes 235 
(N-E-1 ILLNKHID and N-E-5 ILLNKHIDA). Interestingly, one of the responders to this 236 
peptide did not carry the HLA-A*0201 allele (Table 1), indicating this peptide may contain a 237 
different SARS-CoV-2 epitope presented by a different HLA molecule. Whereas these NP 238 
epitopes are targeted by CD8+ T cells, we also detected a CD4+ T cell response targeting 239 
SARS spike epitope S-E-19 which spans between the overlapping peptides of S-203 and S-240 
204. This peptide is known to be presented by HLA-DRB1*0401 in SARS infection. 241 
 242 
The  optimal peptide sequences and their HLA restrictions were confirmed by generating 243 
short term T cell lines and clones, which were tested in ELIspot assays by co-culturing with 244 
peptide loaded HLA matched and unmatched immortalized B lymphoblastoid cell lines 245 
(BCLs) as previously described21. In total 6 CD8+ T cell epitopes restricted by HLA-A*0101, 246 
A*0301, A*1101, B*0702, B*4001 and B*2705 were confirmed (Table 2).  HLA-peptide 247 
pentamers were synthesized comprising 5 peptides bound to the appropriate HLA class I 248 
molecules.  T cell staining was verified by flowcytometry (Fig. 6) and their phenotypes were 249 
determined (Fig. 7). A pentameric HLA-A*0201 with the spike epitope reported 250 
by Shomuradova  et al22, was synthesised. Only one  out of six HLA-A*0201-positive donors 251 
showed detectable staining, but at a very low frequency.  The majority of pentamer stained 252 
SARS-Cov-2 specific CD8+ T cells exhibited central memory (20.7%±8.4%) or effector 253 
memory phenotypes (50.3%±13.3%) (Fig. 7) and early (CD27+CD28+, 43.8%±20.9%) or 254 
intermediate (CD27+CD28-, 49.3%±21.0%) differentiation phenotypes. Overall, multiple 255 
peptides containing epitopes and immunodominant regions were defined from 42 subjects 256 
who had recovered from COVID-19. The regions were located in the majority of SARS-CoV-257 
2 structural and non-structural proteins including spike, M, NP and ORF proteins, with CD8+ 258 





This study demonstrates the presence of robust memory T cell responses specific for SARS-263 
CoV-2 in the blood of donors who have recovered from Covid-19. The broader and stronger 264 
SARS-CoV-2 specific T cell responses in patients who had severe disease may be the result 265 
of higher viral loads and may reflect a poorly functioning early T cell response that failed to  266 
control the virus, in addition to other factors such as direct virus-induced pathology 267 
associated with larger viral inoculums or poorer innate immunity. Alternatively, it is possible 268 
that the T cell response was itself harmful and contributes to disease severity. Consistent 269 
with recent reports from Grifoni et al and Sekine et al 17, 23,  a particularly high frequency of 270 
spike protein-specific CD4+ T cell responses was observed in patients who had recovered 271 
from COVID-19. This is very similar to influenza virus infection, where viral surface 272 
hemagglutinin (HA) elicited mostly CD4+ T cell responses, whereas the majority of CD8+ T 273 
cell responses were specific to viral internal proteins 24. Understanding the roles of different 274 
subsets of T cells in protection or  pathogenesis is a crucial question for COVID-19. The 275 
timing and strength of the first  T cell responses, could be critical in determining this balance 276 
at an early stage of the infection.  277 
  278 
Among the 41 peptides containing T cell epitopes that were identified in this study, six 279 
immunodominant epitope groups (peptides) were  frequently targeted by T cells in many 280 
donors, including three in spike (29%, 24%, 18%), two in membrane protein (32%, 47%) and 281 
one in nucleoprotein (35%).  The immunodominant peptide regions identified here may 282 
include multiple epitopes restricted by different HLAs (both class I and II, such as S-34 and 283 
NP16)  with immunodominance preferences imposed by the antigen processing pathways. 284 
Whether or not these dominant responses play a role in immune protection merits further 285 
investigation in larger prospective cohorts.  286 
 287 
A higher proportion of CD8+ T cell responses was observed in mild disease, suggesting the 288 
potential protective role of CD8+ T cell responses in mild disease or pathogenic role of 289 
CD4+ T cell responses in severe disease which merits further investigation.  290 
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 291 
The majority of pentamer-binding CD8+ T cells were effector memory and central memory 292 
with early and intermediate differentiation phenotypes, with functional potential on antigen 293 
re-exposure. Because the number of donors studied was limited and they would likely show 294 
diverse TCRs, peptide/MHC affinities and antigen sensitivities for the different epitopes, it 295 
was not possible to make a detailed analysis comparing mild and severe cases. However, 296 
the groundwork, including epitope identification, was laid for future studies that can address 297 
this important issue. 298 
 299 
Multiple strong dominant T cell responses were seen in study subjects, specific for the M 300 
and NP proteins. Dominant epitope regions within NP (NP-16) were detected in 35% of 301 
study subjects and M (M-20 and M24) were detected in 32% and 47%. In addition, a higher 302 
proportion of multi-cytokine producing M/NP-specific compared to spike-specific CD8+ T 303 
cells was observed in subjects who had recovered from mild disease. A similar trend was 304 
also observed in severe cases, although was not significant possibly due to fewer cases.  305 
These data strongly suggest NP and M have potential for inclusion within future vaccines so 306 
as to stimulate strong effector T cell responses. Furthermore, T cells responding to these 307 
antigens may be more cross-reactive 18. 308 
 309 
 IFN- producing SARS-CoV-2 specific T cell responses were not observed in 16 healthy 310 
unexposed volunteers differing from recently published reoorts by Grifoni et al17  and  Braun 311 
et al25, both of which used peptide stimulated induction of activation markers (AIM) assays.   312 
On the other hand, in a recent immunogenicity study of a recombinant adenovirus type-5 313 
(Ad5) vectored COVID-19 vaccine human phase I trial in 108 volunteers without pre-314 
exposure to COVID-19), spike-specific T cell responses, measured IFN-ELISpot and 315 
intracellular cytokine stimulation (ICS) assays, were not found before vaccination6. These 316 
differences could result from differences in sensitivity of the detection methods, AIM versus. 317 
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IFN- production assays.  IFN- -ELISpot and ICS are well-established methods for 318 
evaluating antigen specific T cells, used in different virus infections and vaccine studies, that 319 
have direct functional relevance 24, 26, 27, 28. The AIM assay is more recently developed assay, 320 
capable of detecting early responding T cells, that is independent of cytokine production. 321 
Both methods are valid but differ in sensitivity and possible functional relevance.  However, it 322 
is also possible that different circulating coronaviruses have been previously present in the 323 
different geographical populations studied, giving cross reactive responses in some regions 324 
but not others, as suggested by Le Bert et al18 .  These T-cell cross reacting viruses could 325 
include not only SARS-CoV-1 and  human “common cold” coronaviruses, but also other 326 
unknown coronaviruses of animal origin.  It is also known that very sensitive assays can 327 
detect not only  pre-existing naïve antigen specific CD4+ T cells but also memory CD4+ T 328 
cells. The latter are potentially primed by other microbes that cross react with viruses as 329 
diverse as CMV, HIV-1 and Ebolavirus in most unexposed humans 29, 30.  Therefore, similar 330 
findings with SARS-CoV-2 peptides do not necessarily mean the T cells were primed by 331 
previous infecting coronaviruses. Indeed, the implications of  pre-existing cross-reactivity to 332 
seasonal coronavirus and other viruses for COVID-19 immunity merits further detailed 333 
investigation as nicely highlighted by Sette A and Crotty S31 . 334 
 335 
This study focuses on T cell responses in PBMC. There remains a lack of understanding of 336 
memory T cells (Trm) at the site of infection, which is likely providing the most potent 337 
protection as observed in influenza virus infection32. It is possible that the hierarchy of 338 
immunodominant circulating blood memory T cell pools may not exactly  reflect that of Trm 339 
in the lung17, 33, 34. Therefore, understanding the features of tissue resident memory T cells 340 
and their association with disease severity will be critical and also merits further investigation. 341 
 342 
Taken together, this study has demonstrated strong and broad SARS-CoV-2-specific CD4+ 343 
and CD8+ T cell responses in the majority of humans who had recovered from COVID-19. 344 
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The immunodominant epitope regions and peptides containing T cell epitopes identified in 345 
this study will provide critical tools to study the contribution of SARS-CoV-19 specific T cells 346 
in protection and immune pathology. Identification of non-spike dominant CD8+ T cell 347 
epitopes, suggests the potential importance of including of non-spike protein such as NP, M 348 
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Table 1 Peptides containing T cell epitopes  606 
Peptide Position Amino Acid Sequence
CD4/CD8 
Response
No of subjects 
responded
Spike S-34 166-180 CTFEYVSQPFLMDLE 4/8 10
(n=18) S-39 191-205 EFVFKNIDGYFKIYS na 1
S-42 206-230 KHTPINLVRDLPQGF na 1
S-43 211-225 NLVRDLPQGFSALEP na 1
S-71 351-365 YAWNRKRISNCVADY 4 1
S-77 381-395 GVSPTKLNDLCFTNV 4 1
S-90 446-460 GGNYNYLYRLFRKSN na 1
S-91 451-465 YLYRLFRKSNLKPFE na 1
S-103 506-520 VVLSFELLHAPATVC 4 1
S-106 526-540 GPKKSTNLVKNKCVN 8 1
S-145 721-735 SVTTEILPVSMTKTS na 1
S-150 746-760 STECSNLLLQYGSFC na 1
S-151 751-765 NLLLQYGSFCTQLNR 4 8
S-161 801-815 NFSQILPDPSKPSKR 4 2
S-174 866-880 TDEMIAQYTSALLAG 4 6
S-235 1171-1185 GINASVVNIQKEIDR na 1
S-240 1196-1210 LIDLQELGKYEQYI na 1
S-242 1206-1220 YEQYIKWPWYIWLGF na 1
NP-1 1-17 MSDNGPQNQRNAPRITF 8 3
NP-2 8-25 NQRNAPRITFGGPSDSTG 8 3
NP NP-12 82-95 DQIGYYRRATRRIR na 1
(n=10) NP-15 101-113 MKDLSPRWYFYYL na 1
NP-16 104-121 LSPRWYFYYLGTGPEAGL 4/8 12
NP-46 313-330 AFFGMSRIGMEVTPSGTW na 1
NP-47 321-338 GMEVTPSGTWLTYTGAIK na 1
NP-48 329-346 TWLTYTGAIKLDDKDPNF 4 2
NP-50 344-361 PNFKDQVILLNKHIDAYK 4 1
NP-51 352-369 LLNKHIDAYKTFPPTEPK 8 3
M19 133-150 LLESELVIGAVILRGHLR na 3
M M-20 141-158 GAVILRGHLRIAGHHLGR 4 11
(n=6) M-21 149-166 LRIAGHHLGRCDIKDLPK na 3
M-23 165-181 PKEITVATSRTLSYYKL na 3
M-24 172-188 TSRTLSYYKLGASQRVA 4 16
M-28 201-218 IGNYKLNTDHSSSSDNIA na 1
ORFs ORF-3a-20 145-160 YFLCWHTNCYDYCIPY na 1
(n=7) ORF-3a-27 198-215 KDCVVLHSYFTSDYYQLY na 3
ORF-3a-28 206-225 YFTSDYYQLYSTQLSTDTGV 8 4
ORF-3a-30 224-243 GVEHVTFFIYNKIVDEPEEH na 1
ORF-7a-2 9-25 LITLATCELYHYQECVR na 3
ORF-7a-7 46-63 FHPLADNKFALTCFSTQF na 1
ORF-7a-10 69-86 DGVKHVYQLRARSVSPKL 4 1  607 
Red highlights the overlaps of two adjacent peptides recognised by same subjects; Bold 608 
indicates multiple donor responders; Peptides with underline are the 6 immunodominant 609 
peptides. na: not available610 
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Table 2: List of identified optimal CD8 epitopes 611 
Protein Position Epitope sequence  HLA Restriction 
NP 
9-17 QRNAPRITF B*2705 
105-113 SPRWYFYYL B*0702 
322-331 MEVTPSGTWL B*4001
362-370 KTFPPTEPK A*0301 
362-370 KTFPPTEPK A*1101 
ORF3a 207-215 FTSDYYQLY A*0101 
 612 






















Figure Legends 634 
Fig. 1: Memory T cell responses specific to SARS-CoV-2 virus proteins in 42 635 
convalescent SARS-CoV-2-infected patients. 28 individuals had mild symptoms while 14 636 
showed severe symptoms. PBMC were isolated and IFN- production was detected by 637 
ELISpot after incubation with SARS-CoV-2 peptides. a) Magnitude of IFN- T cell responses 638 
from each individual. Each bar shows the total T cell responses of each individual specific to 639 
all the SARS-CoV-2 protein peptides tested. Each colored segment represents the source 640 
protein corresponding to peptide pools eliciting IFN-γ T cell responses. b) Breadth of T cell 641 
responses from each individual. The breadth of T cell responses was calculated by the 642 
number of peptide pools in the first-dimension (total 29) cells responded to SFU spot forming 643 
units. Experiments were repeated in 35 subjects where sample availability permitted. 644 
 645 
Fig. 2: Comparison of magnitude and breadth of T cell response specific to each viral 646 
protein between convalescent patients with mild symptoms and severe symptoms. 647 
PBMCs were isolated and IFN- production was detected by ELISpot after incubation with 648 
SARS-CoV-2 peptides. a) and b) illustrate the magnitude and the breadth of T cell response 649 
against each viral protein between the groups with mild symptoms (n=28) and with severe 650 
symptoms (n=14), respectively. Overall, magnitude/breadth: p=0.002/p=0.002;  Spike, 651 
magnitude/breadth: p=0.021/0p=0.016; M, magnitude/breadth: p=0.0003/p=0.033; ORF3a, 652 
magnitude/breadth: p<0.0001/p=0.001); ORF8, magnitude/breadth:  p=0.011/p=0.014). Data 653 
are presented as median with interquartile range. Mann-Whitney test was used for the 654 
analysis and two-tailed p value was calculated. *P<0.05, **P<0.01, ***P<0.001, ****P<0.001. 655 
SFU spot forming units; 656 
 657 
Fig. 3: Correlation of T cell responses against SARS-CoV-2 with Spike, RBD and NP-658 
specific antibody responses. a) EPTs-spike b) EPTs-RBD and c) EPTs-NP in association 659 
with overall T cell responses. Red dots represent the patients with severe symptoms 660 
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whereas the mild cases are shown as black dots. n=42. Spearman’s rank correlation 661 
coefficient was used for the correlation analysis. d) Comparison of EPT-spike (p<0.0001), 662 
EPT-RBD (p<0.0001) and EPT-NP (p=0.0004) with mild symptoms (n=28) and severe 663 
symptoms (n=14). Data are presented as median with interquartile range and Mann-Whitney 664 
test was used for comparison. Two-tailed p value was calculated. *** P<0.001; **** P<0.0001 665 
EPT: Endpoint titer 666 
 667 
Fig. 4: Distribution of SARS-CoV-2–specific CD4+ and CD8+ memory T cell responses  668 
Cytokine producing T cells were detected by ICS after incubation with SARS-CoV-2 peptides. 669 
a) and b) Flow cytometric plots represent CD4+T cell and CD8+ T cells expressing IFN-  (x-670 
axis),TNF (y-axis) and/or IL-2 (y-axis) upon stimulation with respective SARS-CoV-2 peptide 671 
pools in examples of mild and severe cases. c) Comparison of relative proportion of SARS-672 
CoV-2 peptide pool-reactive CD8+ T cells between mild (Spike, n=11; M/NP, n=14; ORF/Env, 673 
n=5; Overall: n=14) and severe cases (Spike, n=7; M/NP, n=7; ORF/Env, n=4; Overall, n=8). 674 
Spike, p=0.0268; M/NP, p=0.02; Overall, p=0.0159. The SARS-CoV-2 peptide pool-reactive 675 
CD4+ or CD8+ T cells were identified with at least one of the three cytokines detected: IFN-, 676 
TNF and IL-2. Data shown are as median with interquartile range. Mann-Whitney test was 677 
used for the analysis. Two-tailed p value was calculated. * P<0.05 678 
 679 
Fig. 5: Cytokine profile of SARS-Cov-2-specific T cells. Cytokine production of SARS-680 
Cov-2-specific T cells was assessed by intracellular cytokine staining after incubation with 681 
SARS-CoV-2 peptides. a) Pie charts represent the relative proportions of CD4+ or CD8+ T 682 
cells producing, and the relative proportion of T cells producing one, two and three cytokines 683 
IFN-, TNF and IL-2. Different colored segments represented different pattern of cytokine 684 
production. b) Comparison of the frequency of multifunctional CD8+ T cells targeting Spike 685 
and M/NP.  The open circles and squares represent T cell responses in mild cases and 686 
severe cases, respectively. Mild, p=0.0037; Severe, p=0.3823; Overall, p=0.0231. c) The 687 
relative frequencies of CD4+ and CD8+ T cells expressing CD107a after antigen-stimulation. 688 
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Data shown are from 14 subjects with mild symptoms and 8 with severe symptoms. Mann-689 
Whitney test was used for the analysis. Two-tailed p value was calculated. * P<0.05, 690 
**P<0.01 691 
 692 
Fig. 6: Defined SARS-CoV-2-specific CD8 epitopes. Examples of peptide-MHC Class I 693 
pentamers staining ex-vivo with PBMCs (HLA-B0702, B4001, A1101, A0101 and A0201) or 694 
with cultured cell lines (A0301), 11 donors were tested with positive Pentamer staining.  695 
 696 
Fig. 7: Memory phenotype and differentiation status of SARS-CoV-2-specific CD8+ T 697 
cells. PBMC were isolated and stained with peptide-MHC class I Pentameric complexes and 698 
markers of T cell memory and differentiation. a) Representative FACS plots of gating for 699 
different cell subsets b) and c) Expression of memory markers (CCR7 and CD45RA) and 700 
differentiation markers (CD27 and CD28) on CD8+ Pentamer+ T cells, respectively. n=7 701 
donors. Data are presented as mean ± SEM. 702 
  703 
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Materials and methods 704 
 705 
Ethical Statement 706 
Patients were recruited   from the John Radcliffe Hospital in Oxford, UK, between March and 707 
May 2020 by identification of patients hospitalised during the SARS-COV-2 pandemic and 708 
recruited into the Sepsis Immunomics and ISARIC WHO Clinical Characterisation Protocol 709 
UK (IRAS 260007 and IRAS126600). Patients were sampled at least 28 days from the start 710 
of their symptoms. Unexposed healthy adult donor samples were used from unrelated 711 
studies undertaken between 2017-early 2019. Written informed consent was obtained from 712 
all patients. Ethical approval was given by the South Central - Oxford C Research Ethics 713 
Committee in England (Ref 13/SC/0149), the Scotland A Research Ethics Committee (Ref 714 
20/SS/0028), and the WHO Ethics Review Committee (RPC571 and RPC572, 25 April 715 
2013). 716 
 717 
Clinical definitions 718 
All patients were confirmed to have a test positive for SARS-CoV-2 using reverse 719 
transcriptase polymerase chain reaction (RT-PCR) from an upper respiratory tract 720 
(nose/throat) swab tested in accredited laboratories. The degree of severity was identified as 721 
mild, severe or critical infection according to recommendations from the World Health 722 
Organisation. Patients were classified as ‘mild’ if they did not require oxygen (that is, their 723 
oxygen saturations were greater than 93% on ambient air) or if their symptoms were 724 
managed at home. A large proportion of our mild cases were admitted to hospital for public 725 
health reasons during the early phase of the pandemic even though they had no medical 726 
reason to be admitted to hospital. Severe infection was defined as COVID-19 confirmed 727 
patients with one of the following conditions: respiratory distress with RR>30/min; blood 728 
oxygen saturation<93%; arterial oxygen partial pressure (PaO2) / fraction of inspired O2 729 
(FiO2) <300mmHg; and critical infection was defined as respiratory 730 
failure requiring mechanical ventilation or shock; or other organ failures requiring admission 731 
 29
to ICU. Since the Severe classification could potentially include individuals spanning a wide 732 
spectrum of disease severity ranging from patients receiving oxygen through a nasal 733 
cannula through to non-invasive ventilation we also calculated the SaO2/FiO2 ratio at the 734 
height of patient illness as a quantitative marker of lung damage. This was calculated by 735 
dividing the oxygen saturation (as determined using a bedside pulse oximeter) by the 736 
fraction of inspired oxygen (21% for ambient air, 24% for nasal cannulae, 28% for simple 737 
face masks and 28, 35, 40 or 60% for Venturi face masks or precise measurements for non-738 
invasive or invasive ventilation settings). Patients not requiring oxygen with oxygen 739 
saturations (if measured) greater than 93% on ambient air, or managed at home were 740 
classified as mild disease. Viral swab Ct values were not available for all patients. In addition, 741 
we have standardised all of our analyses to the days since symptom onset. 742 
 743 
Synthetic peptides 744 
A total of 423 15- to 18-mer peptides overlapping by 10 amino acid residues and spanning 745 
the full proteome of the SARS-CoV-2 except ORF-1 (Supplementary Table 1) were designed 746 
using software PeptGen (http://www.hiv.lanl.gov/content/sequence/PEPTGEN/peptgen.html) 747 
and synthesized (purity >75%; Proimmune).  748 
27 previously defined SARS epitopes20 were also synthesised (Supplementory Table 749 
2).Pools of Cytomegalovirus (CMV),Epstein-Barr cirus (EBV) and influenza virus specific 750 
epitope peptides and The human immunodeficiency viruses (HIV) gag were also used as 751 
positive and negative controls.  752 
 753 
2-dimensional peptide matrix system 754 
The overlapping peptides spanning the SARS-CoV-2 were assigned into a 2-dimensional 755 
matrix system in which each peptide was represented in 2 different peptide pools. Each 756 
peptide pool contains no more than 16 individual peptides. The first dimension of the peptide 757 
matrix system was designed so that peptides from different source proteins were separated 758 
into different pools. (Supplemental Table 1).  759 
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 760 
Ex vivo ELISpot assay  761 
IFN-γ ELISpot assays were performed using either freshly isolated or cryopreserved PBMCs 762 
as described previously. No significant difference was observed between responses 763 
generated by fresh or cryopreserved PBMCs as described previously24, 35. 764 
 765 
Overlapping peptides were pooled  and then added to 200,000 PBMCs per test at the final 766 
concentration of 2μg/mL for 16–18 h, the positive responses were confirmed by repeat 767 
ELISPOT assays. To quantify antigen-specific responses, mean spots of the control wells 768 
were subtracted from the positive wells, and the results expressed as spot forming units 769 
(SFU)/106 PBMCs. Responses were considered positive if results were at least three times 770 
the mean of the negative control wells and >25SFU/106PBMCs. If negative control wells 771 
had >30SFU/106 PBMCs or positive control wells (PHA stimulation) were negative, the 772 
results were excluded from further analysis. 773 
 774 
Determination of plasma binding to trimeric spike, RBD and NP by ELISA 775 
MAXISORP immunoplates (442404; NUNC) were coated with 0.125μg of StrepMAB-Classic 776 
(2-1507-001;iba) , blocked with 2% skimmed milk in PBS for one hour and then incubated 777 
with 50μL of 5μg/mL soluble trimeric Spike 2μg/mL or 2% skim milk in PBS. After one hour, 778 
50 μL of serial two-fold dilutions of plasma, from 1:50 to 1:51200 in PBS containing 2% 779 
skimmed milk were added followed by ALP-conjugated anti-human IgG (A9544; Sigma) at 780 
1:10,000 dilution. The reaction was developed by the addition of PNPP substrate and 781 
stopped with NaOH. The absorbance was measured at 405nm. Endpoint titers (EPTs) were 782 
defined as reciprocal plasma dilutions that corresponded to two times the average OD 783 
values obtained with mock. To determine EPTs to RBD and NP, immunoplates were coated 784 
with 0.125ug of Tetra-His antibody (34670; QIAGEN) followed by 2μg/mL and 5μg/mL of 785 
soluble RBD and NP, respectively. 786 
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 787 
Intracellular cytokine staining (ICS)  788 
Intracellular cytokine staining was performed as described previously36, 37 .  Briefly, overnight 789 
rested PBMCs were stimulated with pooled or individual peptides at a final concentration of 790 
10μg/mL for 1 h in the presence of 2μg/mL monoclonal antibodies CD28 and CD49d, and  791 
then for an additional 5h with GolgiPlug, GolgiStop and surface stained with PE-anti-CD107a. 792 
Dead cells were labelled using LIVE/DEAD™ Fixable Aqua dye from Invitrogen; surface 793 
markers including BUV395-anti-CD3, BUV737-anti-CD4, PerCP-Cy5.5-anti-CD8, BV510-794 
anti-CD14 (Biolegend), BV510-anti-CD16 (Biolegend) and BV510-anti-CD19 (Biolegend) 795 
were stained. Cells were then washed, fixed with Cytofix/CytopermTM and stained with PE-796 
Cy7-anti-IFNγ, APC-anti-TNFα (eBioscience), BV421-anti-IL-2 (Biolegend). Negative 797 
controls without peptide-stimulation were run for each sample. All reagents were from BD 798 
Bioscience unless otherwise stated. All samples were acquired on BD LSR Fortessa (BD 799 
Biosciences) flow cytometer and analyzed using FlowJoTM v.10 software (FlowJo LLC). 800 
Peptide pool-reactive CD4+ or CD8+ T cells with frequency lower than 0.05% of CD4+ or 801 
CD8+ T cells respectively were excluded for analysis. Cytokine responses were background 802 
subtracted individually prior to further analysis. To determine the frequency of different 803 
response patterns based on all possible combinations, Boolean gates were created using 804 
IFN-γ, TNF-α and IL-2. Cytokine responses were background subtracted individually prior to 805 
further analysis.  806 
 807 
Pentamer phenotyping 808 
Cryopreserved PBMCs were thawed as described above. A total of 1 × 106 live PBMCs were 809 
labeled with peptide-MHC class I Pentamer-PE (Proimmune, UK) and incubated for 15 min 810 
at 37°C. Dead cells were first labelled with LIVE/DEAD™ Fixable Aqua dye (Invitrogen) and 811 
then with surface markers CD3-BUV395, CD8-PerCP.Cy5.5, CD14-BV510 (Biolegend UK), 812 
CD16-BV510 (Biolegend UK), CD19-BV510 (Biolegend UK), CD28-BV711, CD27-APC-813 
R700, CD45RA-APC-H7 and CCR7-PE-Dazzel 594 (Biolegend UK). All reagents were from 814 
 32
BD Bioscience unless otherwise stated. All samples were acquired on BD LSR Fortessa (BD 815 
Biosciences) flow cytometer and analyzed using FlowJoTM v.10 software (FlowJo LLC). 816 
 817 
Generating short-term T cell lines 818 
Short-term SARS-CoV-2-specific T cell lines were established as previously described 35. 819 
Briefly, 3 × 106 to 5 × 106 PBMCs were pulsed as a pellet for 1 h at 37°C with 10 μM of 820 
peptides containing T cell epitope regions and cultured in R10 at 2 × 106 cells per well in a 821 
24-well Costar plate. IL-2 was added to a final concentration of 100U/mL on day 3 and 822 
cultured for further 10 -14 days.  823 
 824 
Statistical analysis 825 
Statistical analysis was performed with IBM SPSS Statistics 25 and Fig.s were made with 826 
GraphPad Prism 8. Chi-square tests were used to compare ratio difference between two 827 
groups. After testing for normality using Kolmogorov-Smirnov test, Independent-samples t 828 
test or Mann-Whitney U test was employed to compare variables between two groups. 829 
Correlations were performed via Spearman’s rank correlation coefficient. Statistical 830 
significance was set at *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001.  All the tests were 831 
2-tailed.  832 
 833 
Life Sciences Reporting Summary 834 
Further information on research design is available in the Nature Research Reporting 835 
Summary linked to this article. 836 
Data availability 837 
Source data are provided with this paper. The corresponding author can be contacted for 838 
further information. 839 
 840 
Method-Only References: 841 
 842 
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35. Peng, Y. et al. Boosted Influenza-Specific T Cell Responses after H5N1 Pandemic 843 
Live Attenuated Influenza Virus Vaccination. Front Immunol 6, 287 (2015). 844 
 845 
36. Lillie, P.J. et al. Preliminary assessment of the efficacy of a T-cell-based influenza 846 
vaccine, MVA-NP+M1, in humans. Clin Infect Dis 55, 19-25 (2012). 847 
 848 
37. de Silva, T.I. et al. Correlates of T-cell-mediated viral control and phenotype of 849 
CD8(+) T cells in HIV-2, a naturally contained human retroviral infection. Blood 121, 850 
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 1 
Supplementary Fig. 1: Participant characteristics. a) distribution of age, gender and 
days post symptom when sampling of the unexposed healthy controls and SSARS-CoV-2 
infected patients studied. b) and c) Comparison of age (p=0.3465) and days post symptom 
(p=0.4075) when sampling between the patient groups with mild symptoms and severe 
symptoms. The unpaired t test with Welch's correction and Mann-Whitney test were used 






Supplementary Fig. 2: No correlation between overall T cell response of each 
individual and the days post symptom when blood specimen was taken. n=42. Black 
and red dots represent patients with history of mild symptoms and severe symptoms, 
respectively. Spearman’s rank correlation coefficient was used for the correlation analysis, 









(n=14, 1 critical) 
Age, y, median (IQR)  46.0(31.0-53.0) 53.8(47.6-60.9) 60.6(44.9-74.1) 
Male sex  8(53.33) 17(60.71) 9(64.28) 
Days post symptom, 
median (IQR) 
NA 42.5(40.2-55.7) 41.5(40.0-47.5) 
 2 
Supplementary Fig. 3: Magnitude of T cell responses of unexposed healthy 
individuals against SARS-CoV-2 antigens. a) An example of IFN-g ELISpot plate from 
three healthy individuals without SARS-CoV-2 infection. Each individual has been tested 
with four spike pools (Pool 1-4, Pool 5-8, Pool 9-12 and Pool-13-16), 13 first dimension of 
non-spike pools and nine dominant individual peptides containing epitopes, along with six 
control wells including: negative controls with no peptide and peptide pools of irrelevant 
antigens derived from HIV Gag protein; positive controls with PHA and three pools 
of known CD8+ T cell epitopes of human influenza, CMV and EBV viruses (namely FEC 
controls). b) Magnitude of T cell responses of unexposed healthy individuals against 











1 2 3 4 5 6 7 8 9 10 11 12
A Spike-Pool1-4 Pool-O-5 Pool-O-13 ORF7a-2 Spike-Pool1-4 Pool-O-5 Pool-O-13 ORF7a-2 Spike-Pool1-4 Pool-O-5 Pool-O-13 ORF7a-2
B Spike-Pool5-8 Pool-O-6 S-34 OFR3-27 Spike-Pool5-8 Pool-O-6 S-34 OFR3-27 Spike-Pool5-8 Pool-O-6 S-34 OFR3-27
C Spike-Pool9-12 Pool-O-7 S-151 RPMI NEG Spike-Pool9-12 Pool-O-7 S-151 RPMI NEG Spike-Pool9-12 Pool-O-7 S-151 RPMI NEG
D Spike-Pool13-16 Pool-O-8 M-24 HIV Spike-Pool13-16 Pool-O-8 M-24 HIV Spike-Pool13-16 Pool-O-8 M-24 HIV
E Pool-O-1 Pool-O-9 NP-16 FLU Pool-O-1 Pool-O-9 NP-16 FLU Pool-O-1 Pool-O-9 NP-16 FLU
F Pool-O-2 Pool-O-10 S-174 CMV Pool-O-2 Pool-O-10 S-174 CMV Pool-O-2 Pool-O-10 S-174 CMV
G Pool-O-3 Pool-O-11 M-20 EBV Pool-O-3 Pool-O-11 M-20 EBV Pool-O-3 Pool-O-11 M-20 EBV
H Pool-O-4 Pool-O-12 NP-48 PHA Pool-O-4 Pool-O-12 NP-48 PHA Pool-O-4 Pool-O-12 NP-48 PHA
 3 
Supplementary Fig. 4: Correlation between SARS-CoV-2 antigen-specific T cell 
responses and SARS-CoV-2 antigen-specific antibody responses. a), b) and c) 
Correlation of Spike-, RBD-, and NP-specific antibody responses to corresponding antigen-
specific T cell responses. d) Correlation between NP-specific antibody response and Spike-
specific T cell response. n=42. Black and red dots represent patients with history of mild 
symptoms and severe symptoms, respectively. Spearman’s rank correlation coefficient 





Supplementary Fig. 5: Gating strategy of flow cytometry analysis. a) Gating for 
CD4+/CD8+ T cells. Cells were gated on single cell by a forward side scatter gate, followed 
by CD3/ CD4/CD8 gating excluding dead cells, CD14+, CD19+, and CD16+ cells. This gating 
strategy was used for Fig. 4-7 and Supplementary Fig. 6.  b) Gating for IFNg+/-, TNFa+/-, 
IL-2+/-, and CD107a+/- population were based on corresponding negative controls. This 
gating strategy was used for Fig. 4-5. 
 
 
Supplementary Fig. 6: Comparison of Cytokine production of T cells between the 
patients with different disease severity and T cells targeting different viral proteins. 
a) No significant difference in the percentage of CD4+ and CD8+ T cells producing IFN-γ 
and/or TNFα, and/or IL-2 targeting each viral antigen between mild cases (n=14) and 
severe cases (n=8). Data are shown in value of median. b) No significant difference in 
proportion of multifunctional CD4+ T cells targeting spike protein (Mild group, n=12; Severe 
group, n=8) and M/NP protein (Mild group, n=14; Severe group, n=8). Mann-Whitney test 







Supplementary Fig. 7: Confirmation of dominant T cell responses with cultured 
short-term T cell lines.  Patient C-COV19-028 showed a CD4 T cell response to peptide 
S-34 and CD8 T cell response to peptide NP-51. Patient C-COV-19-038 showed CD4 T 
cell response to three dominant peptides: S-151 (weak), S-174, M24 and a CD8 T cell 
response to NP-16. Patient C-COV-19-039 showed CD4 T cell response to peptide S-E-
19, whereas donor C-COV19-031 had a CD4 T cell response targeting peptide M-20. 
PBMCs were stimulated with corresponding peptide pools corresponding to the ex vivo 
ELISpot results and then cultured for 10 days. Cytokine production of the cell lines was 
then examined by ICS upon the stimulation with single peptides. Cells were gated on the 






Supplementary Table 1: Two-dimensional peptide Matrix pools.  
a:  Spike protein: 253 peptides in total 32 pools including 16 pools in 1st dimension and 16 pools in 2nd dimension 
 
b: Non-spike proteins: total 29 pools,  13 pools in 1st dimension including ORF3a (35 peptides in 3 pools), ORF6 (7 peptides in 1 pool), 
ORF7a(15 peptides in 1 pool), ORF8(16 peptides in 1 pool), Envelope(9 peptides in 1 pool), Membrane Protein(29 peptides in 2 pools)  
and Nucleoprotein( 59 peptides in 4 pools). 
Pool-17 Pool-18 Pool-19 Pool-20 Pool-21 Pool-22 Pool-23 Pool-24 Pool-25 Pool-26 Pool-27 Pool-28 Pool-29 Pool-30 Pool-31 Pool-32
Pool 1 S-1 S-2 S-3 S-4 S-5 S-6 S-7 S-8 S-9 S-10 S-11 S-12 S-13 S-14 S-15 S-16
Pool 2 S-17 S-18 S-19 S-20 S-21 S-22 S-23 S-24 S-25 S-26 S-27 S-28 S-29 S-30 S-31 S-32
Pool 3 S-33 S-34 S-35 S-36 S-37 S-38 S-39 S-40 S-41 S-42 S-43 S-44 S-45 S-46 S-47 S-48
Pool 4 S-49 S-50 S-51 S-52 S-53 S-54 S-55 S-56 S-57 S-58 S-59 S-60 S-61 S-62 S-63 S-64
Pool 5 S-65 S-66 S-67 S-68 S-69 S-70 S-71 S-72 S-73 S-74 S-75 S-76 S-77 S-78 S-79 S-80
Pool 6 S-81 S-82 S-83 S-84 S-85 S-86 S-87 S-88 S-89 S-90 S-91 S-92 S-93 S-94 S-95 S-96
Pool 7 S-97 S-98 S-99 S-100 S-101 S-102 S-103 S-104 S-105 S-106 S-107 S-108 S-109 S-110 S-111 S-112
Pool 8 S-113 S-114 S-115 S-116 S-117 S-118 S-119 S-120 S-121 S-122 S-123 S-124 S-125 S-126 S-127 S-128
Pool 9 S-129 S-130 S-131 S-132 S-133 S-134 S-135 S-136 S-137 S-138 S-139 S-140 S-141 S-142 S-143 S-144
Pool 10 S-145 S-146 S-147 S-148 S-149 S-150 S-151 S-152 S-153 S-154 S-155 S-156 S-157 S-158 S-159 S-160
Pool 11 S-161 S-162 S-163 S-164 S-165 S-166 S-167 S-168 S-169 S-170 S-171 S-172 S-173 S-174 S-175 S-176
Pool 12 S-177 S-178 S-179 S-180 S-181 S-182 S-183 S-184 S-185 S-186 S-187 S-188 S-189 S-190 S-191 S-192
Pool 13 S-193 S-194 S-195 S-196 S-197 S-198 S-199 S-200 S-201 S-202 S-203 S-204 S-205 S-206 S-207 S-208
Pool 14 S-209 S-210 S-211 S-212 S-213 S-214 S-215 S-216 S-217 S-218 S-219 S-220 S-221 S-222 S-223 S-224
Pool 15 S-225 S-226 S-227 S-228 S-229 S-230 S-231 S-232 S-233 S-234 S-235 S-236 S-237 S-238 S-239 S-240
Pool 16 S-241 S-242 S-243 S-244 S-245 S-246 S-247 S-248 S-249 S-250 S-251 S-252 S-253
Pool-O-14 Pool-O-15 Pool-O-16 Pool-O-17 Pool-O-18 Pool-O-19 Pool-O-20 Pool-O-21 Pool-O-22 Pool-O-23 Pool-O-24 Pool-O-25 Pool-O-26 Pool-O-27 Pool-O-28 Pool-O-29
Pool-O-1 ORF3a-1 ORF3a-2 ORF3a-3 ORF3a-4 ORF3a-5 ORF3a-6 ORF3a-7 ORF3a-8 ORF3a-9 ORF3a-10 ORF3a-11 ORF3a-12 ORF3a-13 ORF3a-14 ORF3a-15 ORF3a-16
Pool-O-2 ORF3a-17 ORF3a-18 ORF3a-19 ORF3a-20 ORF3a-21 ORF3a-22 ORF3a-23 ORF3a-24 ORF3a-25 ORF3a-26 ORF3a-27 ORF3a-28 ORF3a-29 ORF3a-30 ORF3a-31 ORF3a-32
Pool-O-3 ORF3a-33 ORF3a-34 ORF3a-35
Pool-O-4 ORF6-1 ORF6-2 ORF6-3 ORF6-4 ORF6-5 ORF6-6 ORF6-7
Pool-O-5 ORF7a-1 ORF7a-2 ORF7a-3 ORF7a-4 ORF7a-5 ORF7a-6 ORF7a-7 ORF7a-8 ORF7a-9 ORF7a-10 ORF7a-11 ORF7a-12 ORF7a-13 ORF7a-14 ORF7a-15
Pool-O-6 ORF8-1 ORF8-2 ORF8-3 ORF8-4 ORF8-5 ORF8-6 ORF8-7 ORF8-8 ORF8-9 ORF8-10 ORF8-11 ORF8-12 ORF8-13 ORF8-14 ORF8-15 ORF8-16
Pool-O-7 Env-1 Env-2 Env-3 Env-4 Env-5 Env-6 Env-7 Env-8 Env-9
Pool-O-8 M-1 M-2 M-3 M-4 M-5 M-6 M-7 M-8 M-9 M-10 M-11 M-12 M-13 M-14 M-15 M-16
Pool-O-9 M-17 M-18 M-19 M-20 M-21 M-22 M-23 M-24 M-25 M-26 M-27 M-28
Pool-O-10 NP-1 NP-2 NP-3 NP-4 NP-5 NP-6 NP-7 NP-8 NP-9 NP-10 NP-11 NP-12 NP-13 NP-14 NP-15 NP-16
Pool-O-11 NP-17 NP-18 NP-19 NP-20 NP-21 NP-22 NP-23 NP-24 NP-25 NP-26 NP-27 NP-28 NP-29 NP-30 NP-31 NP-32
Pool-O-12 NP-33 NP-34 NP-35 NP-36 NP-37 NP-38 NP-39 NP-40 NP-41 NP-42 NP-43 NP-44 NP-45 NP-46 NP-47 NP-48
Pool-O-13 NP-49 NP-50 NP-51 NP-52 NP-53 NP-54 NP-55 NP-56 NP-57 NP-58
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Supplementary Table 2: HLA class I typing of CD8+ epitope peptides in subjects with confirmed responses. Each patient listed made a 
CD8 T cell response to the peptides shown. Optimal epitopes and the corresponding HLA-restriction were predicted by IEDB analysis tool 
(http://tools.iedb.org/mhci). Red highlights are the predicted optimal epitope sequences.  
 
A1 A2 B1 B2 Cw1 Cw2
NP-1 MSDNGPQNQRNAPRITF B*2705/06 C-COV19-044 02:07 11:01 27:06 40:01 03:04 07:02
NP-2 NQRNAPRITFGGPSDSTG C-COV19-047 24:02 24:02 27:05 27:05 01:02 02:02
C-COV19-025 02:01 24:02 27:05 44:02 02:02 05:01/03
NP-16 LSPRWYFYYLGTGPEAGL B*0702 C-COV19-001 02:01 23:01 07:02 49:01 07:01 07:02
LSPRWYFYYLGTGPEAGL A*0201 C-COV19-002 03:01 68:02 07:02 49:01 06:02 07:02
LSPRWYFYYLGTGPEAGL Cw*0702 C-COV19-003 02:01 32:01 07:02 44:02 05:01/03 07:02
C-COV19-004 02:01 02:01 07:02 40:01 03:04 07:02
C-COV19-005 01:01/04N 02:01 07:02 40:01 01:02 07:02
C-COV19-006 01:01/04N 29:02 07:02 45:01 07:01 07:02
C-COV19-007 01:01/04N 01:01/04N 07:02 07:02 07:02 07:02
C-COV19-035 11:01 11:01 07:02 07:05/06 03:04 07:02
C-COV19-036 01:01/04N 03:01 07:02 52:01 07:02 12:02
C-COV19-038 02:01 24:02 07:02 51:01 04:01 07:02
C-COV19-045 01:01/04N 02:01 07:02 45:01 06:02 07:02
C-COV19-046 02:01 03:01 07:02 44:02 05:01/03 07:02
NP-E-3 MEVTPSGTWL B*4001 C-COV19-021 02:01 31:01 40:01 40:01 03:04 03:04
C-COV19-044 02:07 11:01 27:06 40:01 03:04 07:02
NP-51 LLNKHIDAYKTFPPTEPK A*0301 C-COV19-028 02:01 03:01 15:01 44:02 03:03 07:04/11
C-COV19-036 01:01/04N 03:01 07:02 52:01 07:02 12:02
NP-51 LLNKHIDAYKTFPPTEPK A*1101 C-COV19-035 11:01 11:01 07:02 07:05/06 03:04 07:02
ORF3a-27 KDCVVLHSYFTSDYYQLY A*0101 C-COV19-022 01:01/04N 01:01/04N 08:01 08:01 07:01 07:02
ORF3a-28 YFTSDYYQLYSTQLSTDTGV C-COV19-036 01:01/04N 03:01 07:02 52:01 07:02 12:02
C-COV19-037 01:01/04N 26:01 08:01 38:01 07:01 12:03
C-COV19-040 01:04N 03:01 27:05 57:01 01:02 06:02
S-34 CTFEYVSQPFLMDLE Cw*0702 C-COV19-035 11:01 11:01 07:02 07:05/06 03:04 07:02





Predicted        
HLA Restriction
ORF
Protein Peptide ID Peptide sequence
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Supplementary Table 3: Known SARS epitopes with identical sequences to SARS-CoV-
2 , and Tetramers/Pentamers. Red highlights the epitope responses detected in the patients 
who had recovered from COVID-19, whether by tetramer/pentamer staining or ELISpot assay. 
Peptide ID Epitope Protein MHC allele Tetramer/Pentamer 
N-E-01 ILLNKHID NP HLA-A*02:01  Y 
N-E-02 AFFGMSRIGMEVTPSGTW NP NA 
 
N-E-03 MEVTPSGTWL NP HLA-B*40:01 I Y 
N-E-04 GMSRIGMEV NP HLA-A*02:01 I Y 
N-E-05 ILLNKHIDA NP HLA-A*02:01 I Y 
N-E-06 ALNTPKDHI NP HLA-A*02:01 I Y 
N-E-07 IRQGTDYKHWPQIAQFA NP NA 
 
N-E-08 KHWPQIAQFAPSASAFF NP NA 
 
N-E-09 LALLLLDRL NP HLA-A*02:01 I Y 
N-E-10 LLLDRLNQL NP HLA-A*02:01 I Y 
N-E-11 LLNKHIDAYKTFPPTEPK NP NA 
 
N-E-12 LQLPQGTTL NP HLA-A*02:01 I Y 
N-E-13 AQFAPSASAFFGMSR NP NA  
 
N-E-14 AQFAPSASAFFGMSRIGM NP NA 
 
N-E-15 RRPQGLPNNTASWFT NP NA I 
 
N-E-16 YKTFPPTEPKKDKKKK NP NA 
 
S-E-17 GAALQIPFAMQMAYRF Spike HLA-DRA*01:01,HLA-
DRB1*07:01 
Y 
S-E-18 MAYRFNGIGVTQNVLY Spike HLA-DRB1*04:01 Y 
S-E-19 QLIRAAEIRASANLAATK Spike HLA-DRB1*04:01 Y 
S-E-20 FIAGLIAIV  Spike HLA-A*02:01 Y 
S-E-21 ALNTLVKQL Spike  HLA-A*02:01 I Y 
S-E-22 LITGRLQSL Spike  HLA-A2 I Y 
S-E-23 NLNESLIDL Spike  HLA-A*02:01 I Y 
S-E-24 QALNTLVKQLSSNFGAI Spike  HLA-DRB1*04:01 Y 
S-E-25 RLNEVAKNL Spike  HLA-A*02:01 I Y 
S-E-26 VLNDILSRL Spike HLA-A*02:01 I Y 



















Supplementary Table 4: 
 
Oxford Immunology Network Covid-19 response: T cell Immunity Team  
Team leader: Graham Ogg, 
Barbara Kronsteiner, Anthony Brown, Emily Adland, Patpong Rongkard, Anna Csala, Helen 
Brown, Nicola Robinson, Panagiota Zacharopoulou, Vinicius Adriano, Prabhjeet Phalora, 
Oliver Sampson, Carl-Philipp Hackstein, Nicholas Lim, Matt Edmans, Senthil Chinnakannan, 
Rachael Brown, Ali Amini, Mathew Jones, Mohammad Ali, Timothy Donnison, Matt Pace, Ane 
Ogbe, Donal Skelly, Lizzie Stafford, Helen Fletcher, Lian Lee, Prathiba Kurupati, Rachel 
Etherington, Nicholas Provine, Hashem Koohy, Chloe Hyun-Jung Lee, Yanchun Peng, Guihai 
Liu, Xuan Yao, Zixi Yin, Danning Dong, Mariolina Salio, Giorgio Napolitani, Susanna Dunachie, 
Eleanor Barnes, John Frater, Georgina Kerr, Philip Goulder, Paul Klenerman, Andrew 
McMichael, Tao Dong. 
 
Supplementary Table 5: ISARIC 4C Investigators  
  
Consortium Lead Investigator: J Kenneth Baillie,  
Chief Investigator: Malcolm G Semple 
Co-Lead Investigator: Peter JM Openshaw.  
ISARIC Clinical Coordinator: Gail Carson.  
Co-Investigators: Beatrice Alex, Benjamin Bach, Wendy S Barclay, Debby Bogaert, Meera 
Chand, Graham S Cooke, Annemarie B Docherty, Jake Dunning, Ana da Silva Filipe, Tom 
Fletcher, Christopher A Green, Ewen M Harrison, Julian A Hiscox, Antonia Ying Wai Ho, 
Peter W Horby, Samreen Ijaz, Saye Khoo, Paul Klenerman, Andrew Law, Wei Shen Lim, 
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